Paris, France and Camberley, UK – 27 September 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 26 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group
Visit PageCategory: Services
RÉSULTATS SEMESTRIELS 2019 Croissance à deux chiffres du chiffre d’affaires EBITDA positif
Paris, France et Camberley, Royaume-Uni – le 26 Septembre 2019 – Novacyt (ALTERNEXT : ALNOV ; AIM ; NCYT), spécialiste mondial des diagnostics cliniques, publie ce jour ses résultats financiers non audités pour les six mois clos le 30 juin 2019. http://novacyt.com/wp-content/uploads/2019/09/Novacyt-half-year-2019-results-PR-25-9-19-FINAL-FRENCH.pdf
Visit PageHALF YEAR RESULTS Double-digit revenue growth EBITDA profit
Paris, France and Camberley, UK – 26 September 2019 – Novacyt (ALTERNEXT: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces unaudited results for the six months ended 30 June 2019. http://novacyt.com/wp-content/uploads/2019/09/Novacyt-half-year-2019-results-PR-25-9-19-FINAL-ENGLISH.pdf
Visit Page